Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-1252 plus osimertinib in EGFR TKI resistant NSCLC
NCT04001777Phase 1Active, not recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jul 2019
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelcitoclax in non-small cell lung cancer (NSCLC), sponsored by Ascentage Pharma. Primary endpoints: Maximum Tolerated Dose at 21 days and Recommended Phase 2 Dose at 21 days. Started Jul 2019; status: active, not recruiting.
02
Drugs
pelcitoclax
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04001777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04001777.